reports
BlackRock® Canada Announces Final April Cash Distributions for the iSh...
BlackRock® Canada Announces Final April Cash Distributions for the iShares® Premium Money Market ETF TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final April 2025 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on April 25, 2025 will receive cash distributions payable on April 30, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund Ticker Cash Distribution Per ...
Blackrock Inc: 1 director
A director at Blackrock Inc sold 2,000 shares at 852.006USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
BlackRock® Canada Announces April Cash Distributions for the iShares® ...
BlackRock® Canada Announces April Cash Distributions for the iShares® ETFs TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the April 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly basis. Unitholders of record of the applicable iShares ETF on April 25, 2025 will receive cash distributions payable in respect of that iShares ETF on April 30, 2025. Details regarding the “per unit” distr...
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conf...
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight...
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Vi...
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investor...
Liquidia Corporation to Present at the 24th Annual Needham Virtual Hea...
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investors” page of Liquidi...
Liquidia Corporation Announces FDA Acceptance of New Drug Application ...
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder FDA sets PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pul...
Liquidia Announces Poster Presentations at the American Thoracic Socie...
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company ...
BlackRock® Canada Announces Final March Cash Distributions for the iSh...
BlackRock® Canada Announces Final March Cash Distributions for the iShares® Premium Money Market ETF TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final March 2025 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on March 26, 2025 will receive cash distributions payable on March 31, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFundTicker CashDistributionPer Uni...
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its four...
Liquidia Corporation Reports Full Year 2024 Financial Results and Prov...
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx)Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative the...
BlackRock® Canada Announces March Cash Distributions for the iShares® ...
BlackRock® Canada Announces March Cash Distributions for the iShares® ETFs TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the March 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada, which pay on a monthly or quarterly basis. Unitholders of record of the applicable iShares ETF on March 26, 2025, will receive cash distributions payable in respect of that iShares ETF on March 31, 2025. Details regarding the “per unit” ...
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available a...
Liquidia Corporation Strengthens Financial Position by Amending Health...
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million MORRISVILLE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreement with HealthCare Royalty (“HCRx”) to provide for up to an additional $100 million of financing in three tranches (the “Sixth Amendment”), subject to certain closing conditions including th...
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial...
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipate...
Liquidia Corporation to Report Full Year 2024 Financial Results on Mar...
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at . A rebroadcast of the...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit ...
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clin...
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression - The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression - The open-label extension stage of the Phase 2b clinical trial continues to enroll patients to evaluate the safety and efficacy of a second dose of BPL-003 - As previously reported, the Phase 2a study of BPL-003 in patients with ...
BlackRock® Canada Announces Final February Cash Distributions for the ...
BlackRock® Canada Announces Final February Cash Distributions for the iShares® Premium Money Market ETF TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final February 2025 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on February 25, 2025 will receive cash distributions payable on February 28, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund Ticker Cash Distri...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health C...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Monday, March 3 at 11:50 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.